Tools and Technology

Gefitinib for Advanced NSCLC Patients With EGFR Mutation

Karen J. Oishi, MSN, APRN, ANP-BC, GNP-BC, OCN®

From University of Texas MD 
Anderson Cancer Center, Houston, Texas

The author has no potential conflicts of interest to disclose.

Correspondence to Karen J. Oishi, MSN, APRN, ANP-BC, GNP-BC, OCN, University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Unit 432, Houston, TX 77030. E-mail: koishi@mdanderson.org


J Adv Pract Oncol 2011;2:46–48 | DOI: 10.6004/jadpro.2011.2.1.5 | © 2011 Harborside Press®


  



For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.